MiMedx Group, Inc. (MDXG)

Market Cap	1.07B
Revenue (ttm)	334.51M
Net Income (ttm)	74.16M
Shares Out	147.60M
EPS (ttm)	0.49
PE Ratio	14.88
Forward PE	23.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	243,109
Open	7.20
Previous Close	7.29
Day's Range	7.19 - 7.31
52-Week Range	5.47 - 9.27
Beta	1.38
Analysts	Strong Buy
Price Target	12.25 (+69.55%)
Earnings Date	Apr 30, 2024

About MDXG

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including ...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Joseph H. Capper
• Employees: 895
• Stock Exchange: NASDAQ
• Ticker Symbol: MDXG

Analyst Forecast

According to 4 analysts, the average rating for MDXG stock is "Strong Buy." The 12-month stock price forecast is $12.25, which is an increase of 69.55% from the latest price.

Price Target

$12.25

(69.55% upside)

Analyst Consensus: Strong Buy